DUBLIN--(BUSINESS WIRE)--The "Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
Selective Serotonin Reuptake Inhibitors (SSRIs) are used to treat severe or persistent depression by elevating the extracellular levels of serotonin. The selective serotonin reuptake inhibitors market analysis considers sales of the drugs for depression, anxiety and panic disorder, and other mental conditions.
This analysis also considers the sales of selective serotonin reuptake inhibitors in Asia, Europe, North America, and ROW. In 2018, the depression segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the rising incidence of depression, easy absorption of the drugs through the gastrointestinal tracts, and their selective activity toward 5-HT receptors will significantly help the depression segment in maintaining its leading market position.
Also, our global selective serotonin reuptake inhibitors report has observed market growth factors such as the increased drug dependency associated with SSRIs, rising prevalence of mental illnesses, and favorable drug purchasing policies for patients. However, challenges such as side effects of antidepressants, advent of biologics, and stringent US FDA regulations and approval of psychotropic drugs may hamper the growth of the selective serotonin reuptake inhibitors industry over the forecast period.
Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Overview
Rising prevalence of mental illnesses
The rising prevalence of mental illnesses, especially in the US, has been increasing the sales of neurological drugs such as SSRIs. These drugs have proven efficacy in treating depression. SSRIs are more effective compared with other available antidepressants. The growth potential of the market will attract new entrants. Therefore, the market is expected to record a CAGR of almost 4% during the forecast period.
Growing geriatric population
Mental disorders are common among older adults. The primary reason being most of the geriatric population have two or more chronic health conditions such as cardiovascular disease, hypertension, diabetes, and cancer, which are high-risk factors for mental disorders. The prevalence rate of mental conditions among the geriatric population is rising. Favorable health insurance policies are allowing people of this age group to avail treatment for mental disorders. This is creating market opportunities for vendors. Therefore, the growing geriatric population will have a positive impact on the overall market growth.
With the presence of several major players, the global selective serotonin reuptake inhibitors market is fragmented. This robust vendor analysis is designed to help clients in improving their market position, and in line with this, this report provides a detailed analysis of several leading selective serotonin reuptake inhibitors producers, which include Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, and Pfizer Inc.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
- Market segmentation by application
- Comparison by application
- Depression - Market size and forecast 2018-2023
- Anxiety and panic disorder - Market size and forecast 2018-2023
- Other mental conditions - Market size and forecast 2018-2023
- Market opportunity by application
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Market positioning of vendors
- Vendors covered
- Vendor classification
- Allergan Plc
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- H. Lundbeck AS
- Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/r/469mq2